Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 375

1.

PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES.

Macleod CM, Hodges RG, Heidelberger M, Bernhard WG.

J Exp Med. 1945 Nov 30;82(6):445-65.

2.
3.
4.

SERUM TREATMENT OF EPIDEMIC CEREBRO-SPINAL MENINGITIS.

Flexner S, Jobling JW.

J Exp Med. 1908 Jan 1;10(1):141-203. No abstract available.

5.

The sensitivity of meningococci to sulfadiazine.

SCHOENBACH EB, PHAIR JJ.

Am J Hyg. 1948 Mar;47(2):177-86. No abstract available.

PMID:
18908912
6.

Epidemiological Study of 383 Cases of Meningococcus Meningitis in the City of Milwaukee, 1927-1928 and 1929.

French MR.

Am J Public Health Nations Health. 1931 Feb;21(2):130-8. No abstract available.

7.

Antigenic shift and increased incidence of meningococcal disease.

Harrison LH, Jolley KA, Shutt KA, Marsh JW, O'Leary M, Sanza LT, Maiden MC; Maryland Emerging Infections Program.

J Infect Dis. 2006 May 1;193(9):1266-74. Epub 2006 Mar 28.

8.

Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June-July 2005.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2005 Oct 14;54(40):1023-5.

9.

Severe sepsis and therapy with activated protein C.

Parrillo JE.

N Engl J Med. 2005 Sep 29;353(13):1398-400. No abstract available. Erratum in: N Engl J Med. 2005 Nov 24;353(21):2311.

PMID:
16192486
10.

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.

N Engl J Med. 2005 Sep 29;353(13):1332-41.

11.
12.

Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2005 May 27;54(RR-7):1-21.

13.

Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.

Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE; ABCs Team.

Pediatrics. 2005 May;115(5):1220-32.

PMID:
15867028
14.

Use of variable-number tandem repeats to examine genetic diversity of Neisseria meningitidis.

Yazdankhah SP, Lindstedt BA, Caugant DA.

J Clin Microbiol. 2005 Apr;43(4):1699-705.

15.

Rapid and fatal meningococcal disease due to a strain of Neisseria meningitidis containing the capsule null locus.

Hoang LM, Thomas E, Tyler S, Pollard AJ, Stephens G, Gustafson L, McNabb A, Pocock I, Tsang R, Tan R.

Clin Infect Dis. 2005 Mar 1;40(5):e38-42. Epub 2005 Feb 7.

17.

Naturally-acquired immunity to Neisseria meningitidis group A.

Amir J, Louie L, Granoff DM.

Vaccine. 2005 Jan 11;23(8):977-83.

PMID:
15620470
18.

Bacterial meningitis in Burkina Faso: surveillance using field-based polymerase chain reaction testing.

Parent du Châtelet I, Traore Y, Gessner BD, Antignac A, Naccro B, Njanpop-Lafourcade BM, Ouedraogo MS, Tiendrebeogo SR, Varon E, Taha MK.

Clin Infect Dis. 2005 Jan 1;40(1):17-25. Epub 2004 Dec 8.

19.

Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.

Soriano-Gabarró M, Rosenstein N, LaForce FM.

J Health Popul Nutr. 2004 Sep;22(3):275-85.

PMID:
15609780
20.

The strategy to control New Zealand's epidemic of group B meningococcal disease.

O'Hallahan J, Lennon D, Oster P.

Pediatr Infect Dis J. 2004 Dec;23(12 Suppl):S293-8.

PMID:
15597072
Items per page

Supplemental Content

Write to the Help Desk